使用灭活的非复制型的修饰的痘苗病毒安卡拉(MVA)作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂的组合
- 专利权人:
- 纪念斯隆-凯特琳癌症中心
- 发明人:
- 邓亮,斯图尔特·苏曼,杰德·D·沃尔卓克,塔拉·马拉胡,戴培红,王伟亿
- 申请号:
- CN201680023964.5
- 公开号:
- CN107735103A
- 申请日:
- 2016.02.25
- 申请国别(地区):
- CN
- 年份:
- 2018
- 代理人:
- 摘要:
- 本公开涉及有感染能力但非复制的灭活修饰的痘苗安卡拉(MVA)及其作为免疫治疗单独或与免疫检查点阻断剂组合用于治疗恶性实体瘤的用途。具体实施方案涉及在被诊断患有实体恶性肿瘤的受试者中诱导免疫应答。
- 来源网站:
- 中国工程科技知识中心
相关发明人
相关专利
- Combination immunotherapy approach for treatment of cancer
- USE OF INACTIVATED NONREPLICATING MODIFIED VACCINIA VIRUS ANKARA (MVA) AS MONOIMMUNOTHERAPY OR IN COMBINATION WITH IMMUME CHECKPOINT BLOCKING AGENTS FOR SOLID TUMORS
- Use of inactivated nonreplicating modified vaccinia virus ankara (MVA)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
- USE OF INACTIVATED NONREPLICATING MODIFIED VACCINIA VIRUS ANKARA (MVA) AS MONOIMMUNOTHERAPY OR IN COMBINATION WITH IMMUME CHECKPOINT BLOCKING AGENTS FOR SOLID TUMORS
- Use of an inactivated non-replicative modified vaccinia virus anchora as a single immunotherapy for solid tumors or in combination with an immuno checkpoint blocking agent